1,4-dihydropyridine-3,5-dicarboxylic acid ester derivatives and pharmaceutical compositions
Abstract
Abstract 1,4-Dihydropyridine-3,5-dicarboxylic acid ester derivatives of the general formula: <IMAGE> or acid addition salts thereof, wherein W is -CH= or -N=; Y is -CH=CH-, -O-, -S-, -CH=N(O)p- (p is zero or 1) or -N(R)- (R is hydrogen or lower alkyl); X1, X2 and X3 are the same or different, and are each hydrogen, halogen, nitro, trifluoromethyl, cyano or lower alkylthio; Z is aryl or 5- or 6-membered aromatic heterocyclic ring (which may have a substituent or two or three substituents which may be the same or different, and the substituent may be halogen, lower alkyl, lower alkoxy, lower alkanoylamino, cyano, nitro, lower alkylthio, trifluoromethyl, sulfamoyl, di-lower alkylsulfamoyl, amino or di-lower alkylamino); <IMAGE> is 5- to 7-membered heterocyclic ring which may have nitrogen atom, oxygen atom, sulfur atom or unsaturated bond on the ring, and may be substituted by lower alkyl, lower alkoxycarbonyl, lower alkanoylamino, ethylenedioxy or -(CH2)m-OR4 (R4 is hydrogen, lower alkyl or lower alkanoyl and m is 0, 1 or 2); R1 and R2 are the same or different, and are each lower alkyl; R3 is lower alkyl, aralkyl, heteroaralkyl; and n is an integer 1 to 5. Such compounds are useful as antihypertensive agents and as therapeutic agents for cardiac and cerebral circulation disorders.
Inventors
- 👤 Kazuhiko Araki
- 👤 Hideki Ao
- 👤 Jun Inui
- 👤 Kenichi Aihara
Bibliographic Details
Claims Analysis
Total Claims: 8References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1989-10-20 | 1990-04-21 | 1990-10-21 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1993-10-20 | 1994-04-21 | 1994-10-21 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1997-10-20 | 1998-04-21 | 1998-10-21 | $7700.00 | Window Closed / Lapsed |